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“Life is that which can mix oil and water”
– Robert Frost
Mary Ellen Avery was a force of Nature.
I first met her while I was a graduate stu-
dent at McGill University in the early 70’s.
She and her colleagues had been studying
the effects of glucocorticoids on fetal lung
maturation and surfactant production, and
had stumbled onto a curious “neighbor
effect” – when they treated one of the fetal
rabbits in the womb by direct injection,
they found an effect on the maturation
of the lungs in the collateral pups. I was
studying fetal endocrinology at the time
in Claude Giroud’s Laboratory at Mon-
treal Children’s Hospital, and had access
to radiolabeled cortisol, so I could deter-
mine if the hormone was passing from
one fetus to the other. Having demon-
strated this effect, Dr. Avery named me as
a co-author on their paper describing this
phenomenon, which was quite generous of
her – but that was in her nature, as I was
to discover in a 20-year journey with her as
my mentor.
In the spring of 1974, while on an ele-
vator at Montreal Children’s Hospital, Dr.
Avery invited me to join her research group
at Harvard Medical School. She said that
it was important to maintain the highest
scientific standards in developing the bur-
geoning discipline of Neonatology because
she was concerned about doing harm in the
name of doing good. I had already commit-
ted to a post-doctoral position with Jack
Gorski and N.L. First in the NIH Repro-
ductive Endocrine Program at the Uni-
versity of Wisconsin-Madison, so I had to
decline the invitation, with the understand-
ing that I would come to Boston after my
Fellowship. I joined the Joint Program in
Neonatology in July, 1976 as a Research
Associate. During my early years at the
Boston Lying-In Hospital (BLI), where in
the 1950s Dr. Avery had previously dis-
covered that Hyaline Membrane Disease
was due to surfactant deficiency in preterm
newborns, I conducted studies on the phys-
iologic role of hormones in fetal lung devel-
opment in support of the clinical use of
antenatal steroids to accelerate the produc-
tion of surfactant. Antenatal steroid treat-
ment dramatically improved the survival
of preterm infants. It is considered one
of the major breakthroughs of twentieth
century medicine, saving the lives of hun-
dreds of thousands of newborns. During
the course of the first clinical trials of ante-
natal steroids for the prevention of Respira-
tory Distress Syndrome, it was found that
males were much less responsive to such
treatment than females, reprising my inter-
est in the sexual dimorphism of fetal devel-
opment, the subject of my Masters’ thesis
in graduate school at McGill. As always,
Dr. Avery was open to whatever we wanted
to study, so one of her Neonatal Fellows,
Heber Nielsen, and I began a 20-year inves-
tigation of this mechanism in trying to
maximize the benefit of antenatal steroid
therapy.
During that era, the Director of the
Joint Program in Neonatology, H. William
Taeusch, asked me to start a clinical labo-
ratory for the measurement of lung surfac-
tant at the BLI. Since this was a direct exten-
sion of my basic scientific work, I accepted
the challenge. The laboratory began pro-
cessing amniotic fluid samples in the spring
of 1977 in parallel with the advent of
the clinical implementation of antenatal
steroids. At that time, the standard method
for measuring surfactant was the L/S ratio,
which was known to lack sensitivity and
specificity, but prior to the implementation
of steroid therapy the management of
preterm birth was essentially passive, so
that method was adequate. But with the
onset of the use of antenatal steroids, there
was a sea change in Neonatology, the fetus
becoming a patient treated in the womb.
To improve on the antenatal testing for
lung maturation, I developed the Saturated
Phosphatidylcholine Assay, which was far
superior to the L/S Ratio, being more than
90% accurate in predicting the risk of Res-
piratory Distress Syndrome. So here was an
example of how the burgeoning discipline
of Neonatology was able to use experimen-
tal methods to optimize the well-being of
preterm newborns.
During that era, we used to have 4th
of July picnics for the Joint Program in
Neonatology. We’d inevitably have to play
softball because it was Dr. Avery’s passion.
She loved to pitch. I was sitting on the side-
lines with my then 2-year old daughter,who
turned to me at one point and said loud
enough so all could hear,“Dr. Avery doesn’t
do that very well.” It was then and there
that I knew I would not live out my days at
Harvard.
Meanwhile, our basic research effort
to understand why males were refractory
to antenatal glucocorticoid treatment was
advancing. We were able to determine that
this was due to a physiologic mechanism by
which androgens delayed the maturation
of the fetal lung, allowing for persistence
of the growth phase of lung development.
This was due to androgen perpetuating the
production of Transforming Growth Fac-
tor Beta in the connective tissue cells sur-
rounding the alveoli, promoting more, but
immature alveoli.
I left Boston in 1991, joining the Neona-
tal Division at the University of Maryland.
It was there that I discovered the Neutral
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Lipid Trafficking phenomenon – the active
movement of lipid substrate between con-
nective tissue and epithelial cells mediated
by specific signaling mechanisms stimu-
lated by both hormones and mechanical
stretch. Dr. Avery had kept in touch with
me, and knew of my interest in the role
of “stretch” in lung development, send-
ing me scientific papers to keep me on-
track. The annual meeting of the Society
for Pediatric Research was held in Balti-
more in 1992, so while attending the meet-
ing Dr. Avery paid me a visit in my new
laboratory. She handed me a book, enti-
tled Soap Bubbles: Their Colors and Forces
Which Mold Them, by C.V. Boys, saying
that everything she knew about lung sur-
factant was in that book! Telling me in
her own way to keep it simple (KISS).
In fact her perennial question to her stu-
dents regarding whether something was
worth studying was “can you live with-
out it?”
Further study of the cellular–molecular
signaling mechanisms for alveolar surfac-
tant homeostasis have led to a fundamen-
tal understanding of how physiology has
evolved. Now there is a way of under-
standing the how and why of physiol-
ogy from its origins in unicellular organ-
isms, providing a “logic” that simplifies
what had become artificially complicated.
I am indebted to Mary Ellen Avery for
giving me the opportunity to pursue new
knowledge.
She is missed.
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